Clinical trials: Inflammatory Bowel Disease, Ulcerative Colitis Type
- Condition Inflammatory Bowel Disease, Ulcerative Colitis Type
- Funder type Industry (pharma, biotech, devices)
Inflammatory Bowel Diseases, Colitis, Ulcerative
A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)
The main aim of this study is to check the disease activity in people with moderate to severe ulcerative colitis and Crohn's disease.
- Conditions
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
- Trial name
- RISE-MX (NCT04873700)
- Where
- 12 sites in Mexico
- Volunteers
- 335 people
- Sponsor
- Takeda
Ulcerative Colitis
Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)
Primary Objective: To assess the long term safety and tolerability of SAR339658 Secondary Objective: To assess the long term efficacy of SAR339658
- Trial name
- NCT01861249
- Testing
- SAR339658
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sanofi
Colitis, Ulcerative
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice
The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
- Trial name
- NCT05369832
- Testing
- Ozanimod
- Where
- 85 sites in United States
- Volunteers
- 139 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis (UC)
A Study for HSK47388 in Participants With Ulcerative Colitis
The purpose of this protocol is to evaluate the efficacy and safety of HSK47388 as therapy in participants with moderately to severely active ulcerative colitis .
- Trial name
- NCT07335055
- Testing
- HSK47388
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Ulcerative Colitis
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis
This study will examine the safety and efficacy in subjects with mild to moderate ulcerative colitis, as measured by Modified Mayo Score, Modified Baron Score, IBDQ, calprotectin and other assessments.
- Trial name
- NCT01839214
- Testing
- VB-201 160mg
- Where
- 3 sites in Bulgaria, Hungary and 1 more
- Volunteers
- 112 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Ulcerative Colitis
A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis
This is a Phase Ib clinical study to evaluate the safety, tolerance, pharmacokinetics and efficacy of AK101 in subjects with moderately to severely active ulcerative colitis.
- Trial name
- NCT06281704
- Testing
- AK101 IV, AK101 SC, AK101 IV/AK101 SC
- Where
- 12 sites in China
- Volunteers
- 34 people
- Sponsor
- Akeso
Ulcerative Colitis
Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients
This is a Phase IIa (proof of concept), randomized, double blind, placebo-controlled, multicentre clinical trial to evaluate the safety and efficacy of daily PBF-677 oral treatment during 28 days in Ulcerative colitis (UC)…
- Trial name
- ADENOIBD (NCT03773952)
- Testing
- PBF-677
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Palobiofarma SL
Ulcerative Colitis (UC)
Efficacy & Safety of TD-1473 in Ulcerative Colitis
A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with up to 60 weeks of treatment.
- Trial name
- RHEA (NCT03758443)
- Testing
- TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C
- Where
- 188 sites in United States, Australia and 20 more
- Volunteers
- 239 people
- Sponsor
- Theravance Biopharma
Ulcerative Colitis
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
- Trial name
- NCT02958865
- Testing
- PF-06700841, PF-06651600
- Where
- 189 sites in United States, Austria and 17 more
- Volunteers
- 319 people
- Sponsor
- Pfizer
Ulcerative Colitis
A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers
The purpose of this study is to understand if multiple oral doses of BMS-986166 are safe and well tolerated in healthy patients.
- Trial name
- NCT03038711
- Testing
- BMS-986166
- Where
- United States
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection…
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT04018599
- Testing
- 40 mg MSB11022
- Where
- 2 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Healthy, Colitis, Ulcerative
A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis
The purpose of this study is to evaluate safety and tolerability of JNJ 66525433 compared with placebo after administration of: 1) single ascending oral doses of JNJ 66525433 administered to healthy participants (Part 1), 2)…
- Trial name
- NCT04457960
- Testing
- JNJ-66525433
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of MT-1303 in subjects with inflammatory bowel disease.
- Trial name
- NCT01666327
- Testing
- MT-1303
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Tanabe Pharma Corporation
Ulcerative Colitis
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy with an option for open-label treatment…
- Trial name
- CALDOSE-1 (NCT03341962)
- Testing
- IMU-838
- Where
- 131 sites in United States, Albania and 17 more
- Volunteers
- 263 people
- Sponsor
- Immunic AG
Ulcerative Colitis
Trial on Profermin and Fresubin in Ulcerative Colitis
This study aim to investigate the effect of Profermin versus Fresubin in the dietetic treatment of active ulcerative colitis.
- Trial name
- CUPE2 (NCT01193894)
- Testing
- Profermin, Fresubin
- Where
- Denmark
- Volunteers
- 73 people
- Sponsor
- Nordisk Rebalance A/S
Colitis, Ulcerative
A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis
GSK1605786 is an oral antagonist specific for the chemokine receptor CCR9 in development for treatment of small bowel and colonic Crohn's disease (CD).
- Trial name
- NCT01658605
- Testing
- GSK1605786
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Ulcerative Colitis
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis…
- Trial name
- NCT05507203
- Testing
- ABX464
- Where
- 264 sites in United States, Argentina and 22 more
- Volunteers
- 639 people
- Sponsor
- Abivax S.A.
Colitis, Ulcerative
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M
IBD98-M-2002 is a phase 2a , Randomized, Double blind, Placebo-controlled of IBD98-M Delayed Release capsules in subjects with Mild to Moderately Ulcerative Colitis to investigate the clinical efficacy of IBD98-M delayed release…
- Trial name
- NCT02493712
- Testing
- High dose, Low dose
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Ulcerative Colitis
ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.
This is a multi-center trial in the US and Europe to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis…
- Trial name
- NCT00063830
- Testing
- Alicaforsen
- Where
- United States
- Sponsor
- Ionis Pharmaceuticals, Inc.